G-CSF/anti-G-CSF antibody complexes drive the potent recovery and expansion of CD11b(+)Gr-1(+) myeloid cells without compromising CD8(+) T cell immune responses

BACKGROUND: Administration of recombinant G-CSF following cytoreductive therapy enhances the recovery of myeloid cells, minimizing the risk of opportunistic infection. Free G-CSF, however, is expensive, exhibits a short half-life, and has poor biological activity in vivo. METHODS: We evaluated wheth...

Descripción completa

Detalles Bibliográficos
Autores principales: Rubinstein, Mark P, Salem, Mohamed L, Doedens, Andrew L, Moore, Caitlin J, Chiuzan, Cody, Rivell, Guillermo L, Cole, David J, Goldrath, Ananda W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850648/
https://www.ncbi.nlm.nih.gov/pubmed/24279871
http://dx.doi.org/10.1186/1756-8722-6-75

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850648/
https://www.ncbi.nlm.nih.gov/pubmed/24279871
http://dx.doi.org/10.1186/1756-8722-6-75

Ejemplares similares